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Abstract
Background: Isolation of Aspergillus from lower respiratory samples is associated with colonisation in high
percentage of cases, making it of unclear significance. This study explored factors associated with diagnosis
(infection vs. colonisation), treatment (administration or not of antifungals) and prognosis (mortality) in
non-transplant/non-neutropenic patients showing repeated isolation of Aspergillus from lower respiratory samples.
Methods: Records of adult patients (29 Spanish hospitals) presenting ≥2 respiratory cultures yielding Aspergillus
were retrospectively reviewed and categorised as proven (histopathological confirmation) or probable aspergillosis
(new respiratory signs/symptoms with suggestive chest imaging) or colonisation (symptoms not attributable to
Aspergillus without dyspnoea exacerbation, bronchospasm or new infiltrates). Logistic regression models (step–wise)
were performed using Aspergillosis (probable + proven), antifungal treatment and mortality as dependent variables.
Significant (p < 0.001) models showing the highest R2 were considered.
Results: A total of 245 patients were identified, 139 (56.7%) with Aspergillosis. Aspergillosis was associated
(R2 = 0.291) with ICU admission (OR = 2.82), congestive heart failure (OR = 2.39) and steroids pre-admission
(OR = 2.19) as well as with cavitations in X-ray/CT scan (OR = 10.68), radiological worsening (OR = 5.22) and COPD
exacerbations/need for O2 interaction (OR = 3.52). Antifungals were administered to 79.1% patients with
Aspergillosis (100% proven, 76.8% probable) and 29.2% colonised, with 69.5% patients receiving voriconazole alone
or in combination. In colonised patients, administration of antifungals was associated with ICU admission at
hospitalisation (OR = 12.38). In Aspergillosis patients its administration was positively associated (R2 = 0.312) with
bronchospasm (OR = 9.21) and days in ICU (OR = 1.82) and negatively with Gold III + IV (OR = 0.26), stroke
(OR = 0.024) and quinolone treatment (OR = 0.29). Mortality was 78.6% in proven, 41.6% in probable and 12.3% in
colonised patients, and was positively associated in Aspergillosis patients (R2 = 0.290) with radiological worsening
(OR = 3.04), APACHE-II (OR = 1.09) and number of antibiotics for treatment (OR = 1.51) and negatively with species
other than A. fumigatus (OR = 0.14) and aspergillar tracheobronchitis (OR = 0.27).
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Conclusions: Administration of antifungals was not always closely linked to the diagnostic categorisation
(colonisation vs. Aspergillosis), being negatively associated with severe COPD (GOLD III + IV) and concomitant
treatment with quinolones in patients with Aspergillosis, probably due to the similarity of signs/symptoms between
this entity and pulmonary bacterial infections.
Keywords: Aspergillus, COPD, Clinical management, Aspergillosis
Background
Isolation of Aspergillus from lower respiratory samples
is associated with colonisation in high percentage of
cases, being of unclear significance because it may rep-
resent a temporary passage, a long-term benign car-
riage or a sign preceding invasive disease since the
incubation period is unknown [1,2]. Invasive disease
has been described as disease of immunocompromised
patients, and for high risk patients (those with bone
marrow or solid organ transplant, neutropenia or
haematological cancer [3]) standard definitions of op-
portunistic infection (proven, probable or possible) to
express disease certainty have been internationally
agreed [4]. In these type of patients, isolation of Asper-
gillus from lower respiratory tract samples is potentially
significant [5], and acquires relevance since early diag-
nosis seems crucial to improve prognosis of this poten-
tially treatable disease [1,6].
Invasive aspergillosis is increasingly being recognised as
an emerging opportunistic infection in non-neutropenic
patients, with reports on patients receiving immunossu-
pressive therapy that do not impair neutrophils count,
patients with cancer (receiving or not treatment), connect-
ive diseases requiring corticosteroids, liver cirrhosis, eld-
erly patients (that comprise a growing segment of
hospitalised patients), patients with less immunodeficiency
such as patients with chronic obstructive pulmonary dis-
ease (COPD), specially those under steroid therapy, and
ICU patients without apparent predisposing immunodefi-
ciency [7-12].
Sensitivity of culture isolation for invasive infection
varies from 5% to 75%, depending on the population
[10]. Since culture has also poor specificity, it has been
suggested the need for repeated isolation of the same
Aspergillus species as part of the diagnosis of invasive
aspergillosis [13], in a field where the use of diagnostic
tools widely differs between different hospitals.
The aim of this study was to explore implications
for the patient’s management of the repeated isolation
of Aspergillus from lower respiratory samples in non-
transplant, non-neutropenic patients not selected based
on clinical diagnoses, by means of identification of fac-
tors associated with diagnosis (infection vs. colonisa-
tion), with treatment (administration of antifungals) and
with prognosis (mortality).
Patients and methods
Clinical records of adult patients presenting at least two
cultures of evaluable lower respiratory tract samples
yielding Aspergillus in 29 Spanish hospitals were retro-
spectively reviewed to include up to 10 patients in each
centre (the 10 most recent consecutive evaluable
patients with complete clinical records in the period
2001–2010). Eligible clinical records were identified
through microbiology records. Transplant recipients and
patients presenting neutropenia (<1000 neutrophils/
mm3), diagnosis of aspergilloma or allergic bronchopul-
monary aspergillosis were excluded. The study protocol
was approved by the Ethics Committee of Hospital Cen-
tral de la Defensa Gomez Ulla, Madrid, Spain.
Demographic data, underlying illnesses, clinical and
radiological data, laboratory data, previous corticosteroids
intake (within 3 months prior to admission), previous anti-
biotic and antifungal treatments (within 30 days prior to
admission), antifungal treatment during hospitalization
and outcome were recorded. The age-unadjusted Charlson
comorbidity index [14] (age was considered in separate),
the modified McCabe score (Sabadell score) [15], the func-
tional classification according to the New York Heart As-
sociation (NYHA) [16] and the Acute Physiologic and
Chronic Health Evaluation (APACHE) II score were calcu-
lated with recorded data, as well as the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) classifica-
tion for COPD patients [17]. A diagnostic category was
assigned to each patient using criteria adapted from those
defined by Bulpa et al. for COPD patients [1], not consid-
ering the “possible” category since in the present study all
patients required at least two positive Aspergillus cultures
as inclusion criteria. Patients were classified as with
proven aspergillosis (histopathological confirmation),
probable aspergillosis (presence of new respiratory signs/
symptoms with suggestive chest imaging) or colonisation
(symptoms not attributable to Aspergillus without dys-
pnoea exacerbation, bronchospasm or new pulmonary
infiltrates). For data analysis a category named “Aspergil-
losis” was considered by pooling patients with probable as-
pergillosis and proven aspergillosis. Diagnoses of
tracheobronchitis were always based on bronchoscopy
reports included in clinical records. Simple tracheobron-
chitis was considered when the bronchoscopy report
described mucosal inflammation and mucus secretions
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and invasive tracheobronchitis when ulceration and
pseudomembrane formation was observed. Chronic pul-
monary aspergillosis was considered when long-term fi-
brotic lesions with or without necrosis or cavitations had
been recorded in the patient’s clinical records.
Comparisons between proportions were performed by
the χ2 test and the Fisher’s exact test, when necessary. For
quantitative variables, since data did not showed normality
in the Kolmogorov – Smirnoff test, the Kruskal-Wallis and
Mann–Whitney tests, when necessary, were used. Bivariate
analyses were performed comparing all variables between
colonised vs. patients with Aspergillosis, between antifungal
treated vs. non-treated patients and between patients who
died vs. those that did not. Different logistic regression
models (step–wise procedure) were performed using as
dependent variables i) Aspergillosis, ii) antifungal treatment
and iii) mortality, and as independent variables those show-
ing differences (p ≤ 0.1) in bivariate analyses. Interactions
and linear dependence between independent variables were
previously controlled. Statistical analyses were performed
using SPSS v 14 programme (SPSS Inc, Chicago, IL). The
models showing the highest R2 were considered.
Results
A total of 245 clinical records were included in the
study, corresponding to patients attended in the study
centres from October 2002 to July 2010 (19 centres
included 10 patients each and 10 centres included the
remaining 55 patients). Of the 245 patients considered,
106 were categorised as colonised and 139 as patients
with Aspergillosis (125 as probable and 14 as proven as-
pergillosis). Six patients (2.4%) had cystic fibrosis (5
patients classified as colonized and 1 as with probable
aspergillosis). Aspergillus fumigatus was the most fre-
quent species isolated, accounting for 66.9% of total iso-
lates, followed by Aspergillus niger in 6.1% patients and
Aspergillus flavus in 3.7% patients. In a total of 23.3%
patients cultures had been informed as Aspergillus spp.
or other species. A. fumigatus was isolated in all cases
categorised as proven aspergillosis. The serum galacto-
mannan level had been determined in 51 (20.8%)
patients. The result was positive (≥1 ng/ml) in 33.3% (14
out of 42) patients with Aspergillosis while it was nega-
tive in all patients categorised as colonised in which the
test was performed (n = 9). Histopathological examin-
ation was performed in 19 patients, the 14 patients clas-
sified as with proven aspergillosis and another 5 patients
where biopsies were performed and were negative
(patients classified as with probable aspergillosis). In the
14 patients with aspergillosis, histopathological confirm-
ation was obtained by fine needle aspiration biopsy (2
patients), pulmonary biopsy (8 patients), renal biopsy (1
patient) and necropsy (3 patients).
Descriptive analysis
Table 1 shows epidemiological data and comorbidities
present in the study patients distributed by diagnostic
category. Mean age of patients was 68.7 ± 15.2 years
(with 42.9% patients ≥75 years of age and 22.0%
≥80 years), without differences between categories. The
percentage of males was significantly higher among
patients with Aspergillosis (74.8% vs. 63.2% in colonised;
p = 0.05). Significantly higher percentage of patients with
severe COPD (GOLD III + IV) (p = 0.037), congestive
heart failure (p = 0.031) and malignancies (p = 0.011)
were found among patients with Aspergillosis, without
Table 1 Epidemiological data and comorbidities of patients included in the study distributed by diagnostic category;
[n (%)] except where indicated
Total Colonised Aspergillosis
Probable Proven Probable + Proven
No. Patients 245 106 125 14 139
Age (mean ± SD) 68.7 ± 15.2 69.1 ± 16.1 68.9 ± 14.6 64.1 ± 14.5 68.4 ± 14.6
Males 171 (69.8) 67 (63.2) 94 (75.2) 10 (71.4) 104 (74.8)a
Comorbiditiesb
COPD 173 (70.6) 73 (68.9) 91 (72.8) 9 (64.3) 100 (71.9)
Gold III + IV c 111 (67.3) 40 (57.2) 66 (76.7)a 5 (55.6) 71 (74.7)a
Diabetes Mellitus II 43 (17.6) 19 (17.9) 23 (18.4) 1 (7.1) 24 (17.3)
Congestive heart failure 45 (18.4) 13 (12.3) 27 (21.6) 5 (35.7)a 32 (23.0)a
Malignancies 38 (15.5) 10 (9.4) 27 (21.6)a 1 (7.1) 28 (20.1)a
Renal impairment 24 (9.8) 10 (9.4) 12 (9.6) 2 (14.3) 14 (10.1)
Charlson (mean ± SD) 2.61 ± 2.16 2.42 ± 2.03 2.81 ± 2.29 2.21 ± 1.76 2.75 ± 2.75
APACHE (mean ± SD) 13.16 ± 6.86 11.63 ± 6.12 14.13 ± 6.67a 16.14 ± 10.90 14.33 ± 7.18a
ICU admission at any time during hospital stay 58 (23.7) 15 (14.2) 36 (28.8)a 7 (50.0)a 43 (30.9)a
ap ≤ 0.050 vs. colonised; bpresent in ≈ > 10% total patients; camong patients with available data (165 patients in total: 70 colonized, 86 probable and 9 proven).
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significant differences in the Charlson index between
categories. The mean APACHE II score was significantly
higher in patients with Aspergillosis (14.33 vs. 11.63 in
colonised; p = 0.004), reaching a value of 16.14 in
patients with proven aspergillosis. Overall prognosis
(McCabe score) was non fatal in 60.0% patients, long-
term fatal (>6 months) in 31.0% patients and short-term
fatal (<6 months) in 8.9% patients, without differences
between categories.
Only 18 patients (7.3%) were ambulatory, 72.2% cate-
gorised as colonised and 27.8% as with probable asper-
gillosis. A total of 48.2% patients had been initially
admitted in Pneumology, 23.3% in Internal Medicine,
11.4% in the Intensive Care Unit (ICU) and 9.8% in
other wards, without differences between diagnostic cat-
egories. Admission in the ICU as initial ward was more
frequent among proven cases (28.6%) than among prob-
able (11.2%) or colonised cases (9.4%), although differ-
ences did not reach statistical significance (p = 0.085 vs.
probable and p = 0.058 vs. colonised). ICU admission at
any time during hospitalisation (Table 1) was signifi-
cantly higher among patients with Aspergillosis (30.9%)
than among those colonised (14.2%) (p = 0.001), with
50.0% admission rate among those with proven aspergil-
losis (p = 0.004 vs. colonised) and 28.8% among those
with probable aspergillosis (p = 0.007 vs. colonised).
Table 2 shows imaging data of patients distributed by
diagnostic categories. Significantly (p < 0.001) higher per-
centage of patients showing infiltrates and cavitations
was found (both in X-ray and CT scan) in the group of
patients with Aspergillosis than in colonised patients.
Worsening of radiological findings in successive X-ray
was also significantly more frequent among patients with
Aspergillosis (36.7% vs. 6.7% colonised, p < 0.001). CT
scan was more frequently requested in patients further
categorised as having Aspergillosis than in those cate-
gorised as colonised (64.7% vs. 46.2%, p = 0.004), being
up to 78.6% among patients with proven aspergillosis.
The halo and the air crescent signs were only found in 4
and 3 cases, respectively, of Aspergillosis.
Table 3 shows intake of steroids, antibiotics and anti-
fungals dividing patients by diagnostic categories. Prior
to admission, the percentage of patients with Aspergil-
losis that had received corticosteroids was significantly
higher than those colonised (51.8% vs. 27.4%, p < 0.001)
due to the subgroup of patients receiving accumulated
doses >100 mg (81.9% vs. 58.6%, p = 0.033). During hos-
pitalisation, 75.5% patients received steroids without dif-
ferences between diagnostic categories. A total of 35.9%
patients received antibiotics prior to admission and
82.0% received them during hospitalisation, without dif-
ferences between diagnostic categories in both cases.
Antifungal treatment was initiated after culture request
in 79.1% patients further categorised as having Aspergil-
losis (100% proven cases and 76.8% probable cases)
and in 29.2% colonised patients (p < 0.001). Voriconazole
was the most frequent antifungal used, with up to
69.5% patients receiving this compound alone or in
combination with other antifungals. In patients with
Aspergillosis, antifungal treatment was voriconazole as
monotherapy in 51.8% cases, voriconazole plus other
antifungals in 22.7% cases and other antifungals (ampho-
tericin, caspofungin, fluconazole and itraconazole) alone
or in combination in 25.5% cases.
Table 4 shows clinical presentations and outcome by
diagnostic category. A total of 54.6% patients with
Aspergillosis presented invasive pulmonary aspergillosis,
18.4% simple tracheobronchitis, 16.3% chronic pulmonary
Table 2 Imaging data corresponding to patients included in the study distributed by diagnostic category; [n (%)]
Total Colonised Aspergillosis
Probable Proven Probable + Proven
No. patients with chest Rx 244 105 125 14 139
Infiltrates 134 (54.9) 46 (43.8) 76 (60.8)a 12 (85.7)a 88 (63.3)a
Nodules 37 (15.2) 13 (12.4) 24 (19.2) 0 (0.0) 24 (17.3)
Cavitations 21 (8.6) 0 (0.0) 19 (15.2)a 2 (14.3)a 21 (15.1)a
Pleural effusion 25 (10.2) 7 (6.7) 16 (12.8) 2 (14.3) 18 (12.9)
Worsening radiological findings 58 (23.8) 7 (6.7) 43 (34.4)a 8 (57.1)a 51 (36.7)a
No. patients with CT Scan 139 (56.7) 49 (46.2) 79 (63.2)a 11 (78.6)a 90 (64.7)a
Infiltrates 78 (56.1) 19 (39.6) 48 (60.0)a 11 (100)a 59 (64.8)a
Nodules 56 (40.3) 14 (28.6) 39 (49.4)a 3 (27.3) 42 (46.7)a
Cavitations 33 (23.7) 5 (10.2) 23 (29.1)a 5 (45.5)a 28 (31.1)a
Halo sign 4 (2.9) 0 (0.0) 3 (3.8) 1 (9.1) 4 (4.4)
Air crescent sign 3 (2.2) 0 (0.0) 3 (3.8) 0 (0.0) 3 (3.3)
ap ≤ 0.05 vs. colonised.
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aspergillosis and 8.5% invasive tracheobronchitis. All 14
patients with proven aspergillosis presented pulmonary in-
fection: 71.4% invasive aspergillosis and 28.6% chronic as-
pergillosis. Significantly higher mortality was found in
proven (78.6%) than in probable aspergillosis (41.6%) (p =
0.018) or colonisation (12.3%) (p < 0.001), as well as in
probable aspergillosis vs. colonisation (p < 0.001). Aspergil-
lus was involved as cause of death (with or without others)
in 78.5% patients with proven aspergillosis compared with
32.0% in those with probable aspergillosis (p = 0.002) and
0% in those colonised (p < 0.001).
Factors defining infection vs. colonisation
In the multivariate analysis exploring variables asso-
ciated with diagnostic categories (colonisation vs. Asper-
gillosis), which included all variables showing
significance (p < 0.1) in the bivariate analysis previously
performed, the logistic regression was statistically
significant (p < 0.001, R2 Cox = 0.291). Aspergillosis was
associated with ICU admission at any time (p = 0.012;
OR = 2.82, 95% CI = 1.26-6.37), congestive heart failure
(p = 0.044; OR = 2.39, 95% CI = 1.03-5.55) and the intake
of steroids prior to admission (p = 0.021; OR = 2.19, 95%
CI = 1.13-4.27) in addition to variables suggesting Asper-
gillosis as the presence of cavitations in X-ray and/or CT
scan (p < 0.001; OR = 10.68, 95% CI = 3.61-31.64), the
worsening of radiological findings (p = 0.001; OR = 5.22,
95% CI = 2.04-13.33) and the interaction between COPD
exacerbations and need for O2 (p < 0.001; OR = 3.52,
95% CI = 1.75-7.11).
Variables associated with administration of antifungals
Table 5 shows variables with statistical significance
(p < 0.1) in the bivariate analysis performed compar-
ing patients treated with antifungals vs. those not trea-
ted, considering the total population, colonised patients
Table 3 Steroids, antibiotic and antifungals intake [n (%)] by diagnostic category
Total Colonised Aspergillosis
Probable Proven Probable + Proven
No. patients 245 106 125 14 139
Steroids intake before admission 101 (41.2) 29 (27.4) 64 (51.2)a 8 (57.1)a 72 (51.8)a
≥20 mg/day 59 (58.4) 15 (51.7) 40 (62.5) 4 (50.0) 44 (61.1)
Accumulated dose >100 mg 76 (75.2) 17 (58.6) 52 (81.3)a 7 (87.5) 59 (81.9)a
Accumulated dose >700 mg 20 (19.8) 6 (20.7) 11 (17.2) 3 (37.5) 14 (19.4)
Antibiotic treatment before admission 88 (35.9) 34 (32.1) 47 (37.6) 7 (50.0) 54 (38.8)
Antifungal treatment after culture request 141 (57.6) 31 (29.2) 96 (76.8)a 14 (100)a 110 (79.1)a
Voriconazole as monotherapy 68 (48.2) 11 (35.5) 55 (57.3) 2 (14.3) 57 (51.8)
Voriconazole + other antifungals 30 (21.3) 5 (16.1) 18 (18.8) 7 (50.0) 25 (22.7)
Total patients receiving voriconazole 98 (69.5) 16 (51.6) 73 (76.1) 9 (64.3) 82 (74.5)
Other antifungals 43 (30.5) 15 (48.4) 23 (24.0) 5 (35.7) 28 (25.5)
ap ≤ 0.05 vs. colonised.
Table 4 Clinical presentations and outcome by diagnostic category
Total Colonised Aspergillosis
Probable Proven Probable + Proven
No. patients 245 106 125 14 139
Invasive pulmonary aspergillosis 77 (31.4) 68 (54.4) 10 (71.4) 78 (56.1)
Chronic pulmonary aspergillosis 23 (9.4) 19 (15.2) 4 (28.6) 23 (16.5)
Simple tracheobronchitis 26 (10.6) 26 (20.8) 0 (0.0) 26 (18.7)
Invasive tracheobronchitis 12 (4.9) 12 (9.4) 0 (0.0) 12 (8.6)
Mortality 76 (31.0) 13 (12.3) 52 (41.6)a 11 (78.6)a,b 63 (45.3)a
a) Death attributable to Aspergillus 7 (2.9) 0 (0.0) 4 (3.2) 3 (21.4)a, b 7 (5.0)
b) Death attributable to Aspergillus and to other causes 44 (18.0) 0 (0.0) 36 (28.8)a 8 (57.1)a 44 (31.7)a
a) + b) 51 (20.9) 0 (0.0) 40 (32.0)a 11 (78.5)a, b 51 (36.7)
Death not attributable to Aspergillus 25 (10.2) 13 (12.3) 12 (9.6) 0 (0.0) 12 (8.6)
Results are expressed as “n (%)”
ap < 0.001 vs. colonised; bp < 0.02 vs. probable.
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and patients with Aspergillosis. The multivariate analysis
performed including the variables shown in the Table
arose the following results:
a) Total population
The multivariate analysis was statistically
significant (p < 0.001, R2 Cox = 0.221) and
antifungal treatment was associated with stay in
the ICU (p < 0.001; OR = 4.78, 95% CI = 2.20-
10.36) and the presence of two or more
radiological findings (infiltrates and/or nodules
and/or cavitations) in X-ray and/or CT scan
(p < 0.001; OR = 2.43, 95% CI = 1.67-3.53) and
negatively associated with severe liver disease
(p = 0.015; OR = 0.15, 95% CI = 0.03-0.69).
b) Patients categorised as colonised
In the multivariate analysis the logistic regression
was significant (p = 0.001) but showed a weak
association (R2 Cox = 0.118).Antifungal treatment
was only associated with ICU admission at hospita-
lization (p = 0.002; OR = 12.38, 95% CI = 2.44-62.92).
c) Patients categorised as with Aspergillosis
The multivariate analysis was statistically
significant (p < 0.001, R2 Cox = 0.312) and
antifungal treatment was positively associated with
days of stay in the ICU (p = 0.021; OR = 1.82, 95%
CI = 1.09-3.05) and presence of bronchospasm
(p = 0.001; OR = 9.21, 95% CI = 2.63-32.21) and
negatively associated with GOLD III + IV
(p = 0.024; OR = 0.26, 95% CI = 0.08-0.84), stroke
(p = 0.009; OR = 0.024, 95% CI = 0.01-0.40) and
concomitant treatment with quinolones (p = 0.034;
OR = 0.29, 95% CI = 0.09-0.91).
Variables associated with mortality
Table 6 includes variables showing statistical significance
in the bivariate analysis comparing dead patients vs.
those that survived considering the total population,
colonised patients and patients with Aspergillosis. The
multivariate analysis performed including the variables
shown in the Table arose the following results:
a) Total population
The multivariate analysis was statistically
significant (p < 0.001, R2 Cox = 0.261) and
mortality was associated with malignancies
(p < 0.001; OR = 4.65, 95% CI = 2.05-10.58), intake
of steroids (whether prior or during admission)
(p = 0.005; OR = 4.33, 95% CI = 1.55-12.09),
antifungal treatment (p < 0.001; OR = 3.68, 95%
CI = 1.81-7.49), and the APACHE II score
(p < 0.001; OR = 1.14, 95% CI = 1.07-1.20) and
negatively associated with COPD (p = 0.045;
OR = 0.44, 95% CI = 0.20-0.98).
b) Patients categorised as colonised
In the multivariate analysis the logistic regression
Table 5 Significant variables in the bivariate analysis of patients receiving vs. not receiving antifungals, [n (%)] except
where indicated
Total patients (n = 245) Colonised (n = 106) Aspergillosis (n = 139)
Treated
(n = 104)
Non-treated
(n = 141)
p Treated
(n = 31)
Non-treated
(n = 75)
p Treated
(n = 110)
Non-treated
(n = 29)
p
Age (X ± SD) 66.7 ± 15.9 71.4 ± 13.8 0.016 66.0 ± 16.7 70.4 ± 15.7 0.086 66.9 ± 15.8 73.9 ± 6.6 0.001
Days to isolation (X ± SD) 12.3 ± 12.2 7.6 ± 7.6 0.001 8.9 ± 6.6 7.0 ± 6.5 0.096 13.2 ± 13.1 9.1 ± 9.6 0.046
COPD 90 (63.8) 83 (79.8) 0.007 15 (48.4) 58 (77.3) 0.005 75 (68.2) 25 (86.2) 0.064
GOLD III + IV 57 (40.4) 54 (51.9) 0.074 8 (53.4) 32 (58.2) 0.568 49 (65.3) 22 (88.0) 0.041
COPD exacerbation 22 (15.6) 3 (2.9) 0.625 6 (19.4) 29 (38.7) 0.070 56 (50.9) 20 (69.0) 0.082
Severe liver disease 3 (2.1) 8 (7.7) 0.058 1 (3.2) 6 (8.0) 0.671 2 (1.8) 2 (6.9) 0.192
Stroke 4 (2.8) 6 (5.8) 0.332 1 (3.2) 2 (2.7) 1.000 3 (2.7) 4 (13.8) 0.035
APACHE II (X ± SD) 13.8 ± 7.6 12.3 ± 5.6 0.076 12.6 ± 7.5 11.2 ± 5.4 0.291 14.1 ± 7.6 15.1 ± 5.1 0.439
ICU admission 47 (33.3) 11 (10.6) 0.001 10 (32.3) 5 (6.7) 0.001 37 (33.6) 6 (20.7) 0.259
ICU stay (days; X ± SD) 7.6 ± 7.9 10.0 ± 3.4 0.113 2.1 ± 4.8 0.3 ± 1.8 0.014 7.9 ± 8.3 2.0 ± 2.8 0.046
Pleuritic pain 19 (13.5) 6 (5.8) 0.049 2 (6.5) 5 (6.7) 1.00 17 (15.5) 1 (3.4) 0.121
Bronchospasm 66 (46.8) 23 (22.1) 0.001 8 (25.8) 17 (22.7) 0.803 58 (52.7) 6 (20.7) 0.003
Infiltrates (X-ray / CT) 102 (72.3) 47 (45.2) 0.001 18 (58.1) 31 (41.3) 0.137 84 (76.4) 16 (55.2) 0.024
Cavitations (X-ray / CT) 31 (22.0) 7 (6.7) 0.001 1 (3.2) 4 (5.3) 0.642 30 (27.3) 3 (10.3) 0.084
Nodules (X-ray / CT) 48 (34.0) 22 (21.2) 0.027 5 (16.1) 16 (21.3) 0.541 43 (39.1) 6 (20.7) 0.081
Treatment with Quinolones 41 (29.1) 42 (40.4) 0.065 12 (38.7) 27 (36.0) 0.827 29 (26.4) 15 (51.7) 0.009
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was significant (p = 0.001; R2 Cox = 0.246).Mortality
was associated with presence of malignancies
(p = 0.001; OR = 31.87, 95% CI = 3.78-258.59) and
worsening of X-ray signs (p = 0.002; OR = 25.38,
95% CI = 3.13-205.89), and it was negatively
associated with COPD (p = 0.030; OR = 0.11,
95% CI = 0.02-0.81).
c) Patients categorised as with Aspergillosis
The multivariate analysis was statistically
significant (p < 0.001, R2 Cox = 0.290) and
mortality was positively associated with
worsening of X-ray signs (p = 0.011; OR = 3.04,
95% CI = 1.28-7.21), number of antibiotics post-
culture (p = 0.013; OR = 1.51, 95% CI = 1.09-2.08),
APACHE II score (p = 0.011; OR = 1.09,
95% CI = 1.02-1.17), and negatively associated
with diagnosis of aspergillar tracheobronchitis
(p = 0.009; OR = 0.27, 95% CI = 0.10-0.73) and
isolation of species other than A. fumigatus
(p = 0.042; OR = 0.14, 95% CI = 0.02-0.93).
Discussion
Three questions arise when physicians face cultures posi-
tive to Aspergillus from lower respiratory samples in non-
immunocompromised/non-neutropenic patients: Is there
colonisation or infection?, should the patient be treated
with antifungals?, and which is the prognosis?, that is, how
to interpret and manage patients from which Aspergillus
is obtained. The retrospective analysis of this series of 245
immunocompetent patients showing at least two respira-
tory cultures positive to Aspergillus, that were further
categorised as colonised, probable or proven aspergillosis,
tried to explore how these three questions are addressed
in the clinical practice. The diagnostic categorization of
patients was based on criteria adapted from those defined
by Bulpa et al. for COPD patients because we expected
that most of the non-neutropenic, non-transplant patients
in our series were this type of patients.
The answer to the first question is important since an
early diagnosis is crucial to improve prognosis [1]. It has
been postulated that isolation of an Aspergillus species
from respiratory samples in critically ill patients (even
when immunocompetent) should not be routinely dis-
carded as colonisation [3], but in elderly patients (com-
monly having underlying diseases) isolation is usually
interpreted as colonisation [10]. Confirmation of infec-
tion obliges the demonstration of histopathological
evidence that is not usually feasible in this type of
patients [18]. Early administration of antifungals may be
life-saving, but overinterpretation of the potential clin-
ical significance of Aspergillus isolation may drive to
needless treatments, with their associated problems and
costs [5,18]. How does clinicians solve the dilemma?
In this study 245 records from patients with at least two
respiratory cultures positive to Aspergillus were identified,
139 of them (56.7%) classified as with Aspergillosis
Table 6 Significant clinical variables in the bivariate analysis of patients with respect to mortality, [n (%)] except where
indicated
Total patients (n = 245) Colonised (n = 106) Aspergillosis (n = 139)
Died
(n = 76)
Survived
(n = 169)
p Died
(n = 13)
Survived
(n = 93)
p Died
(n = 63)
Survived
(n = 76)
p
Days to isolation (X ± SD) 13.0 ± 14.2 9.2 ± 8.5 0.012 6.5 ± 8.5 7.7 ± 6.3 0.126 14.3 ± 14.8 10.8 ± 10.2 0.153
Smokers 17 (22.4) 21 (12.4) 0.047 2 (15.4) 12 (12.9) 0.805 15 (23.8) 9 (11.8) 0.063
COPD 49 (64.5) 124 (73.4) 0.158 8 (61.5) 65 (69.9) 0.549 41 (65.1) 59 (77.6) 0.101
Malignancies 21 (27.6) 17 (10.1) 0.001 4 (30.8) 6 (6.5) 0.015 17 (27.0) 11 (14.5) 0.089
Charlson (X ± SD) 3.20 ± 2.64 2.34 ± 1.85 0.012 4.1 ± 3.2 2.2 ± 1.7 0.019 3.0 ± 2.5 2.5 ± 2.0 0.376
McCabe (Non fatal) 33 (43.4) 114 (67.5) 0.001 2 (15.4) 63 (67.7) 0.001 31 (49.2) 51 (67.1) 0.032
APACHE II (X ± SD) 16.3 ± 7.7 11.7 ± 5.9 0.001 14.0 ± 7.9 11.3 ± 5.8 0.191 16.8 ± 7.6 12.3 ± 6.1 0.001
ICU admission 32 (42.1) 26 (15.4) 0.001 4 (30.8) 11 (11.8) 0.086 28 (44.4) 15 (19.7) 0.002
ICU stay (days; X ± SD) 6.9 ± 7.6 6.8 ± 7.6 0.937 1.9 ± 5.8 0.7 ± 2.5 0.167 2.9 ± 6.0 1.5 ± 4.9 0.017
Dyspnoea 59 (77.6) 114 (67.5) 0.106 6 (46.2) 60 (64.5) 0.201 53 (84.1) 54 (71.1) 0.068
Infiltrates (X-ray / CT) 59 (77.6) 90 (53.3) 0.001 7 (53.8) 42 (45.3) 0.570 52 (82.5) 48 (63.2) 0.011
Cavitations (X-ray / CT) 19 (25.0) 19 (11.2) 0.006 1 (7.7) 4 (4.3) 0.487 18 (28.6) 15 (19.7) 0.237
Worsening X-ray signs 40 (52.6) 18 (10.7) 0.001 4 (30.8) 3 (3.3) 0.002 36 (57.1) 15 (19.7) 0.001
Steroids prior to admission 43 (56.6) 58 (34.3) 0.001 4 (30.8) 25 (26.9) 0.748 39 (61.9) 33 (43.4) 0.030
Steroids during admission 68 (89.5) 117 (69.2) 0.001 11 (84.6) 63 (67.7) 0.336 57 (90.5) 54 (71.1) 0.004
Antifungal treatment 60 (78.9) 81 (47.9) 0.001 7 (53.8) 24 (25.8) 0.052 53 (84.1) 57 (75.0) 0.187
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(probable + proven) following adapted Bulpa et al. criteria.
This contrasts with other published series where the per-
centage of patients showing Aspergillosis was markedly
lower [3,5,10], probably due to the at least two positive
cultures required as inclusion criteria in our study. In this
sense, a recent study in our country reported 22.1% of
probable invasive pulmonary aspergillosis among hospita-
lized COPD patients with at least one positive culture to
Aspergillus [19]. In addition to signs/symptoms suggestive
of aspergillosis as cavitations in X-ray/CT scan, worsening
of radiological findings and interaction of COPD and need
for O2, according to the multivariate analysis performed,
stay in the ICU, congestive heart failure and previous in-
take of steroids were also positively associated with Asper-
gillosis; all of them factors that had been previously
described [1,6,7]. Although clinical signs/symptoms and
radiological findings are usually non specific in critically ill
patients [3], in our series requests of CT scan and the
galactomannan test were significantly more frequent in
patients further classified as with Aspergillosis than in
those colonised, this suggesting a right clinical suspicion
of colonisation/infection by treating physicians.
Initiation of antifungal treatment and time for initi-
ation is a matter of considerable debate. Clinical mani-
festations of pulmonary aspergillosis may be initially
indistinguishable from bacterial bronchopneumonia
(fever, cough, purulent sputum) [20]. The recovery of
the same Aspergillus species from several respiratory
samples in the course of antibiotic-resistant pneumonia
in patients with risk factors is clearly evocative of the
diagnosis [21]. Therefore it has been proposed that the
isolation of an Aspergillus species from the respiratory
tract in critically ill patients with risk factors (COPD
after corticosteroids exposure, severe underlying disease)
and clinical features of pneumonia indicates prompt
consideration of antifungal treatment [3,7].
In our series (with 72.6% of pulmonary aspergillosis
among patients with Aspergillosis) antifungal treatment
was not initiated in 23.2% patients with probable asper-
gillosis while it was administered to 29.2% of patients
classified as colonised. Administration of antifungals was
negatively associated with the presence of severe liver
disease, probably because of the renal and hepatic tox-
icity of antifungals [11]. ICU admission and days in the
ICU were associated with prescription of antifungals,
both in colonised and aspergillosis patients. Interest-
ingly, in patients with Aspergillosis antifungal treatment
was negatively associated with Gold III + IV and treat-
ment with quinolones. The negative association with
treatment with wide-spectrum quinolones could prob-
ably be linked to the commented similarity of initial
clinical manifestations of pulmonary aspergillosis with
bacterial bronchopneumonia. In addition this could be
the reason for the significantly lower number of severe
COPD patients found among treated vs. non-treated
patients (65.3% vs. 88.0%) in our series when analysing
patients with Aspergillosis. However the percentage of
COPD patients with Aspergillosis (Table 5) that received
antifungal treatment in our series was 75% (75 out of
100), a percentage similar to the one (71%) described in
a published review of 65 cases [22].
Voriconazole was the most frequent antifungal drug,
with 74.5% of treated patients with Aspergillosis receiving
this drug alone or in combined regimens. For primary
treatment of invasive aspergillosis, the triazole voricona-
zole is recommended for most patients [23] and, although
its superiority over lipid formulations of Amphotericin B
or echinocandins has not been proved in the subset of
COPD patients [21], the superiority of voriconazole versus
Amphotericin B has been demonstrated in invasive asper-
gillosis in immunocompromised patients [24].
The high mortality of invasive pulmonary aspergillosis
in non-neutropenic critically ill patients has been attrib-
uted, at least partially, to difficulties in timely diagnosis
caused by insensitive and non specific clinical signs and
lack of unequivocal diagnostic criteria [11] precluding
the early needed treatment. In the present study, as
expected, significant higher mortality was found in
proven than in probable aspergillosis and in the latter
than among colonised patients (78.6% vs. 41.6% vs.
12.3%). Interestingly, COPD was negatively associated
with mortality in colonised patients but not in patients
with Aspergillosis. Higher mortality rates (>90%) in inva-
sive pulmonary aspergillosis than those found in the
present study have been reported in previously published
series in COPD patients, but including only patients in
the ICU [1,22]. Although the strength of the present
study resides in the description of clinical features of as-
pergillosis in a large series of patients with at least two
positive lower respiratory samples, several study limita-
tions should be considered. The retrospective nature of
the study based on information (clinical, radiological
reports. . .) recorded in clinical records from 29 different
hospitals, implies bias derived from inter-hospital differ-
ences in patient’s management. This could specially
affect the management of patients concomitantly pre-
senting other hospital infections and/or organ dysfunc-
tion. In addition most patients in the Aspergillosis
category were classified as “probable aspergillosis”, thus
making difficult to establish firm conclusions due to the
low number of proven cases or patients with CT scan
images as halo sign or air crescent sign.
Conclusions
The analysis of the present series including 245 patients
not selected based on clinical diagnoses but with at least
two cultures of respiratory samples positive to Aspergillus
showed that antifungal treatment is not always closely
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linked to the diagnostic categorisation (colonisation vs.
Aspergillosis). Administration of antifungals in patients
with Aspergillosis was negatively associated with severe
COPD (GOLD III + IV) and concomitant treatment
with quinolones, probably due to the similarity of signs/
symptoms between this entity and pulmonary bacterial
infections.
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